

CUMBERLAND PHARMACEUTICALS INC  
Form 8-K  
January 24, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of  
report  
(date of  
earliest  
event  
reported):  
January  
24, 2019  
(January  
24, 2019)

CUMBERLAND PHARMACEUTICALS INC.

---

(Exact name of registrant as specified in its charter)

Tennessee 001-33637 62-1765329  
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

2525 West End Avenue, Suite 950, Nashville, Tennessee 37203  
(Address of principal executive offices) (Zip Code)

(615) 255-0068  
Registrant's telephone number, including area code:

Not Applicable

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 8.01 Other Events

Cumberland Pharmaceuticals Inc. (“we” or “our”) is a specialty pharmaceuticals company focused on the acquisition, development and commercialization of branded prescription products.

On January 18, 2019, we received notification from the U.S. Food and Drug Administration (“FDA”) setting September 2019 as the Prescription Drug User Fee (“PDUFA”) action date for an approval decision regarding the New Drug Application (“NDA”) for our methotrexate product line.

Our new line of methotrexate products is designed for the treatment of adult and pediatric patients with rheumatoid arthritis, as well as adults with psoriasis. The NDA was accepted for filing by the FDA earlier this month following its submission to the FDA in November 2018. In conjunction with the submission, we remitted a payment of \$1.3 million to the FDA for the PDUFA Application Fee associated with this methotrexate product line NDA.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Dated: January 24, 2019 By: /s/ Michael Bonner

Name: Michael Bonner  
Title: Chief Financial Officer